Last reviewed · How we verify
Aczone Gel
Dapsone reduces inflammation and bacterial growth in acne lesions through its antimicrobial and anti-inflammatory properties.
Dapsone reduces inflammation and bacterial growth in acne lesions through its antimicrobial and anti-inflammatory properties. Used for Acne vulgaris, Rosacea.
At a glance
| Generic name | Aczone Gel |
|---|---|
| Also known as | Dapsone, dapsone |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Drug class | Sulfone antibiotic |
| Target | Bacterial dihydropteroate synthase; neutrophil function modulation |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Dapsone is a sulfone antibiotic that inhibits bacterial protein synthesis and has potent anti-inflammatory effects, particularly effective against Cutibacterium acnes (formerly Propionibacterium acnes). It also suppresses neutrophil function and reduces inflammatory mediators, making it effective for inflammatory acne and rosacea.
Approved indications
- Acne vulgaris
- Rosacea
Common side effects
- Oiliness/greasy skin
- Erythema
- Dryness
- Peeling
Key clinical trials
- Randomized, Triple-Blind, Placebo-Controlled Trial of Topical Dapsone Gel in Patients With Acne Vulgaris (PHASE4)
- Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris (PHASE2)
- Effect of New Topical Preparation for Treatment of Acne Vulgaris (PHASE2)
- Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color (PHASE4)
- DAPSONE GEL7.5%Versus Trichloroacetic Acid 20% ON ACNE VULGARIS (PHASE4)
- Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage. (PHASE3)
- Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris (PHASE3)
- Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aczone Gel CI brief — competitive landscape report
- Aczone Gel updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI